Clinical Trials Directory

Trials / Conditions / KRAS G12C

KRAS G12C

13 registered clinical trials studyying KRAS G12C — 6 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingGlecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
NCT07339839
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 1 / Phase 2
RecruitingBBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1
WithdrawnAMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
NCT06068153
ETOP IBCSG Partners FoundationPhase 2
RecruitingA Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
NCT05983159
Murdoch Childrens Research InstitutePhase 2
RecruitingAdagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
NCT06248606
Ryan Gentzler, MDPhase 2
RecruitingOpen-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1
WithdrawnJDQ443 for KRAS G12C NSCLC Brain Metastases
NCT05999357
Maastricht University Medical CenterPhase 2
RecruitingA Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771
Frontier Medicines CorporationPhase 1 / Phase 2
Active Not RecruitingA Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Adva
NCT06403436
TOLREMO therapeutics AGPhase 1
Active Not RecruitingA Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
NCT05726864
Elicio TherapeuticsPhase 1 / Phase 2
Active Not RecruitingCAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
NCT05631899
Chinese PLA General HospitalPhase 1
CompletedA Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
NCT05005234
Innovent Biologics (Suzhou) Co. Ltd.Phase 1 / Phase 2
AvailableExpanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
NCT07083479
Elicio Therapeutics—